Nothing Special   »   [go: up one dir, main page]

MX2021015338A - Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. - Google Patents

Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.

Info

Publication number
MX2021015338A
MX2021015338A MX2021015338A MX2021015338A MX2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A MX 2021015338 A MX2021015338 A MX 2021015338A
Authority
MX
Mexico
Prior art keywords
pridopidine
symptoms
analog
composition
huntington disease
Prior art date
Application number
MX2021015338A
Other languages
English (en)
Inventor
Michal Geva
Michael Hayden
Elena Berelovich
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/438,508 external-priority patent/US11090297B2/en
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2021015338A publication Critical patent/MX2021015338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a un método de tratamiento de un paciente humano afectado por la enfermedad de Huntington y/o síntomas de la misma, que comprende la administración al paciente de una composición farmacéutica que comprende pridopidina o una sal farmacéuticamente aceptable de la misma y un análogo de la misma o una sal farmacéuticamente aceptable de la misma.
MX2021015338A 2019-06-12 2020-06-12 Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. MX2021015338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/438,508 US11090297B2 (en) 2013-06-21 2019-06-12 Pridopidine for treating huntington's disease
PCT/IL2020/050654 WO2020250234A1 (en) 2019-06-12 2020-06-12 Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof

Publications (1)

Publication Number Publication Date
MX2021015338A true MX2021015338A (es) 2022-01-18

Family

ID=73782137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015338A MX2021015338A (es) 2019-06-12 2020-06-12 Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.

Country Status (11)

Country Link
EP (1) EP3982963A4 (es)
JP (2) JP7436524B2 (es)
CN (1) CN113950328A (es)
AU (1) AU2020293739B2 (es)
BR (1) BR112021024744A2 (es)
CA (1) CA3137633A1 (es)
CL (1) CL2021003312A1 (es)
EA (1) EA202193190A1 (es)
IL (1) IL288940A (es)
MX (1) MX2021015338A (es)
WO (1) WO2020250234A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022084999A1 (en) * 2020-10-20 2022-04-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine and analogs for the treatment of anxiety and depression
CN118649245A (zh) * 2024-08-16 2024-09-17 北京市疾病预防控制中心 聚乙烯吡咯烷酮修饰的钯纳米颗粒在制备治疗亨廷顿舞蹈症的产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US20140088145A1 (en) * 2012-09-27 2014-03-27 Teva Pharmaceutical Industries, Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
BR112015006623A2 (pt) * 2012-09-27 2017-07-04 Teva Pharma laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
PE20170302A1 (es) * 2013-06-21 2017-03-31 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
US11207310B2 (en) * 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline

Also Published As

Publication number Publication date
EP3982963A1 (en) 2022-04-20
CA3137633A1 (en) 2020-12-17
JP7436524B2 (ja) 2024-02-21
CN113950328A (zh) 2022-01-18
AU2020293739B2 (en) 2023-11-30
JP2022535929A (ja) 2022-08-10
EP3982963A4 (en) 2023-06-21
WO2020250234A1 (en) 2020-12-17
IL288940A (en) 2022-02-01
CL2021003312A1 (es) 2022-08-26
EA202193190A1 (ru) 2022-03-24
AU2020293739A1 (en) 2021-12-16
JP2024016113A (ja) 2024-02-06
BR112021024744A2 (pt) 2022-03-22

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2021002321A (es) Nuevos metodos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2016010899A (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
MX2021002322A (es) Nuevos metodos.
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
AR119159A1 (es) Tratamientos de angioedema
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
MD4710B1 (ro) Tratamente terapeutice pe bază de anamorelin
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
EA202193276A1 (ru) Способы лечения холангиокарциномы
EP3919052A4 (en) PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR THE TREATMENT OF RETINAR DISEASES
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2022009776A (es) Tratamiento de la colangitis biliar primaria con elafibranor.
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
MX2019004200A (es) Terapia de combinacion.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага